Calidi Biotherapeutics (NYSEMKT:CLDI) just reported results for the second quarter of 2024.
- Calidi Biotherapeutics reported earnings per share of -$1.40. This was above the analyst estimate for EPS of -$2.20.
- The company did not report any revenue for the quarter.